Results From Six Pivotal Tibotec Trials, Including Head-To-Head Data, Presented At The 11th European AIDS Conference

Data from six pivotal trials investigating Tibotec HIV compounds will be presented at the 11th European AIDS Conference (EACS) in Madrid from 24-27 October 2007. Results from these and other studies examining PREZISTA? (darunavir), the company’s protease inhibitor (PI), and two of its investigational next-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs), TMC125 and TMC278, will be featured in 21 abstracts, including two oral presentations and 19 posters. [click link for full article]

More: continued here

Filed under: HIV / AIDS on October 26th, 2007